115 completed, 70 recruiting, 53 terminated, 47 unknown. 154 Phase 2, 123 Phase 1, 27 Not applicable, 16 Phase 3, 5 Early Phase 1.
Follow Urothelial Carcinoma: new trials by email Literature Review of Urothelial Carcinoma trials Research Report on Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract biospecimen Collection - Urothelial Carcinoma | Recruiting | M.D. Anderson Cancer Center | 50000 | 2026-09-10 | 2026-10-05 | |
| Bladder Preservation or Cystectomy for MIBC Gemzar, Cisplatin, Adrucil - Muscle-Invasive Bladder Carcinoma, Bladder Cancer | Early Phase 1 | Active not recruiting | Dana-Farber Cancer Institute | 20 | 2026-09-02 | 2026-09-15 |
| DBC-664 in Adult Patients With Solid Tumors DBC-664 - Malignant Germ Cell Tumor, Lung Adenocarcinoma | Phase 1 | Recruiting | Duboce Biopharmaceuticals, Inc. | 210 | 2026-07-17 | 2026-09-29 |
| Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01) Sacituzumab Tirumotecan, MMAE-based ADC, Sacituzumab Tirumotecan (Observational Cohort) - Bladder Cancer, Metastatic Urothelial Carcinoma | Phase 2 | Not yet recruiting | Fudan University | 75 | 2026-07-15 | 2026-06-23 |
| SYS6002 vs Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma SYS6002, Investigator's Choice of Chemotherapy - Urothelial Carcinoma | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 406 | 2026-06-20 | 2026-04-13 |
| A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors HH160 - Solid Tumor, Non-small Cell Lung Cancer | Phase 1 | Recruiting | Huahui Health | 299 | 2026-06-11 | 2026-08-21 |
| Maintenance AVElumab After SECond Line Platinum-based Chemotherapy for Metastatic Urothelial Carcinoma Avelumab 800 mg flat-dose IV - Urothelial Carcinoma | Phase 2 | Not yet recruiting | Gruppo Oncologico Italiano di Ricerca Clinica | 144 | 2026-06-01 | 2026-03-10 |
| Nectin-4 Specific LMW PET Probe Imaging in Urothelial Carcinoma 18F-FDG - Urothelial Carcinoma | Not applicable | Recruiting | Peking University Cancer Hospital & Institute | 20 | 2026-05-31 | 2026-03-04 |
| A Study of GEN1106 in Participants With Solid Tumors GEN1106 - Solid Tumors, Urothelial Carcinoma | Phase 1 | Recruiting | Genmab | 103 | 2026-04-14 | 2026-10-06 |
| Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC Intravesical Gemcitabine and Docetaxel - Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Recruiting | Michael A. O'Donnell | 174 | 2026-04-10 | 2026-04-17 |
| A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer BMS-986504, Ipilimumab, Nivolumab - Diffuse Pleural Mesothelioma, Gastroesophageal Carcinoma | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 60 | 2026-04-07 | 2026-09-16 |
| Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer PF-08634404, Enfortumab Vedotin - Urothelial Cancer, Advanced/Metastatic Urothelial Cancer | Phase 1 / Phase 2 | Recruiting | Pfizer | 132 | 2026-03-11 | 2026-10-08 |
| Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma EB-DT-NK-UC101, Cyclophosphamide, Fludarabine - Bladder Cancer, Urothelial Carcinoma | Phase 1 | Recruiting | Beijing Biotech | 42 | 2026-03-02 | 2026-03-25 |
| A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer Metastatic Urothelial Carcinoma, Urothelial Cancer | Completed | Pfizer | 1 | 2026-02-12 | 2026-05-28 | |
| A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma Non-therapeutic Nerve Conduction Studies, Non-therapeutic assessment of patient-reported neuropathy - Neuropathy, Urothelial Carcinoma | Recruiting | Memorial Sloan Kettering Cancer Center | 50 | 2026-01-20 | 2026-05-29 | |
| Circulating Tumor DNA Response In Urothelial Cancer Pembrolizumab & Enfortumab Vedotin (PEV), Pembrolizumab - Urothelial Carcinoma | Phase 2 | Recruiting | University of Oklahoma | 30 | 2026-01-19 | 2026-02-02 |
| Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging - Bladder Cancer, Muscle-Invasive Bladder Carcinoma | Not applicable | Recruiting | Thomas Jefferson University | 70 | 2025-12-23 | 2026-02-17 |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas Cancer Therapeutic Procedure, Questionnaire Administration - Amyloidosis, Basal Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 27 | 2025-12-18 | 2026-09-30 |
| Phase II Study of Trastuzumab Rezetecan or in Combination With Adebrelimab in HER2-Expressing Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC) Adebrelimab, Trastuzumab Rezetecan - Urothelial Carcinoma, Advanced Urothelial Carcinoma | Phase 2 | Recruiting | Sun Yat-sen University | 96 | 2025-11-20 | 2026-04-30 |
Showing 20 of 354. Sign in to see all of them.
Carcinoma, Transitional Cell (354) · Urinary Bladder Neoplasms (100) · Carcinoma, Non-Small-Cell Lung (69) · Carcinoma, Renal Cell (61) · Melanoma (53) · Squamous Cell Carcinoma of Head and Neck (47) · Colorectal Neoplasms (38) · Stomach Neoplasms (34) · Uterine Cervical Neoplasms (34) · Carcinoma, Hepatocellular (32) · Ovarian Neoplasms (31) · Triple Negative Breast Neoplasms (30) · Breast Neoplasms (26) · Small Cell Lung Carcinoma (26) · Neoplasms (24)
Neoplasms, Glandular and Epithelial (353) · Neoplasms by Histologic Type (352) · Carcinoma (345) · Neoplasms (330) · Neoplasms by Site (216) · Urogenital Diseases (195) · Female Urogenital Diseases (192) · Female Urogenital Diseases and Pregnancy Complications (192) · Urogenital Neoplasms (187) · Male Urogenital Diseases (179) · Urologic Diseases (169) · Urologic Neoplasms (157) · Urinary Bladder Diseases (99) · Thoracic Neoplasms (88) · Respiratory Tract Neoplasms (87)
pembrolizumab (47) · Gemcitabine (28) · Nivolumab (27) · atezolizumab (26) · Cisplatin (24) · Carboplatin (19) · avelumab (19) · Docetaxel (18) · Mitomycin (10) · enfortumab vedotin (10) · Ipilimumab (8) · Paclitaxel (8) · toripalimab (8) · Pemetrexed (6) · durvalumab (6)
Memorial Sloan Kettering Cancer Center (8) · Pfizer (8) · UroGen Pharma Ltd. (8) · Changhai Hospital (6) · Fox Chase Cancer Center (6) · Hoffmann-La Roche (6) · National Cancer Institute (NCI) (6) · RemeGen Co., Ltd. (5) · University of Michigan Rogel Cancer Center (5) · Bristol-Myers Squibb (4) · H. Lee Moffitt Cancer Center and Research Institute (4) · Matthew Galsky (4) · National Taiwan University Hospital (4) · Pacific Edge Limited (4) · The Netherlands Cancer Institute (4)
United States (201) · China (58) · Spain (38) · France (33) · Italy (27) · Canada (25) · South Korea (24) · Australia (22) · United Kingdom (21) · Netherlands (18) · Taiwan (18) · Germany (17) · Belgium (16) · Japan (16) · Poland (14)
Matthew Galsky, M.D. (4) · Andrea B Apolo, M.D. (3) · Samuel Funt, MD (3) · Tony Lough, PhD (3) · Abhishek Tripathi, MD (2) · Ajjai Alva, M.D. (2) · Chi-Jung Chung, PhD (2) · Chuangliang Xu, M.D., Ph.D (2)
PMID 29415874, PMID 33037018, PMID 37988648, PMID 38573872, PMID 11352955, PMID 11600601, PMID 12586807, PMID 12771730, PMID 12944571, PMID 15939524, PMID 16034041, PMID 19389012, PMID 19913890, PMID 21502557, PMID 23460707, PMID 23563166, PMID 24089446, PMID 24373477, PMID 24472710, PMID 24669010, PMID 24821881, PMID 24821883, PMID 25257030, PMID 25427282, PMID 25429526, PMID 25772330, PMID 26149529, PMID 26205531, PMID 26421586, PMID 26537069, PMID 27053504, PMID 27160946, PMID 27328856, PMID 27939400, PMID 28625005, PMID 28916371, PMID 29248319, PMID 29329894, PMID 30125350, PMID 30552156, PMID 30570744, PMID 30807645, PMID 31145415, PMID 31400383, PMID 31401903, PMID 31648851, PMID 31753727, PMID 32271672, PMID 32416780, PMID 32473636
2016 (5), 2017 (4), 2018 (4), 2023 (4), 2025 (4), 2019 (2), 2009 (1), 2014 (1), F31CA239330 (1), N01CM00100 (1), P30CA014089 (1), P30CA047904 (1), P50CA196516 (1), R35CA220449 (1), R44CA250824 (1)